SCHEMBL10104438

SCHEMBL10104438

COc1c(C)cc(C(C)(C)C)cc1CN1CCCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
TSHR P16473 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
CACNA1B Q00975 1/20 0.47
KDM4E B2RXH2 5/20 0.43
TDP1 Q9NUW8 3/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
ALOX15 P16050 1/20 0.43
HIF1A Q16665 1/20 0.43
HSD17B10 Q99714 1/20 0.43
POLB P06746 1/20 0.42
MAPK1 P28482 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MAPT P10636 1/20 0.41
GAA P10253 2/20 0.40
XBP1 P17861 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10104443 0.98 ALDH1A1 (0.47) ALDH1A1TSHRMEN1KMT2ACACNA1B
SCHEMBL10104440 0.86 CYP2A13 (0.47) KDM4ECYP3A4POLBHTTCYP2D6
SCHEMBL12401768 0.86 CACNA1B (0.45) ALDH1A1TSHRMEN1KMT2ACACNA1B
SCHEMBL10104476 0.85 MEN1 (0.46) ALDH1A1TSHRMEN1KMT2ACACNA1B
SCHEMBL5118355 0.84 CACNA1B (0.43) ALDH1A1TSHRMEN1KMT2ACACNA1B
SCHEMBL13130588 0.82 MAPK1 (0.43) ALDH1A1TSHRMEN1KMT2ACACNA1B
SCHEMBL5118350 0.79 POLB (0.42) ALDH1A1TSHRMEN1KMT2ACACNA1B
SCHEMBL10104483 0.77 ALDH1A1 (0.46) ALDH1A1TSHRMEN1KMT2ACACNA1B
SCHEMBL10104485 0.76 MAOA (0.44) ALDH1A1TSHRMEN1KMT2AKDM4E
SCHEMBL12724826 0.75 CACNA1B (0.55) ALDH1A1TSHRCACNA1BKDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778929-B2 Substituted heteroaryl inhibitors of B-RAF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-15 US disclosed
US-8653087-B2 Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-18 US disclosed
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 US disclosed
US-20110312939-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312939-A1 NEW CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 ALDH1A1 175/4885TSHR 1287/4885MEN1 254/4885
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS CCNT1, CCNA1, CCND1 ALDH1A1 860/4885TSHR 865/4885MEN1 1575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.